STX7 Antibody

What is STX7 protein and what are its key cellular functions?

STX7 (Syntaxin-7) is a member of the syntaxin family of proteins that function as critical components of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex involved in membrane fusion processes. The canonical human STX7 protein has 261 amino acid residues with a molecular mass of 29.8 kDa . Functionally, STX7 is primarily involved in:

• Mediating vesicle trafficking from the plasma membrane to early endosomes

• Facilitating homotypic fusion of endocytic organelles

• Regulating endocytic trafficking from early endosomes to late endosomes and lysosomes

The protein contains characteristic SNARE domains that enable it to form complexes with other SNARE proteins, facilitating membrane fusion events essential for endosomal-lysosomal pathway function .

What is the tissue distribution and subcellular localization of STX7?

STX7 displays a broad tissue distribution pattern with notable expression in:

Subcellularly, STX7 is predominantly localized to endosomal membranes as a single-pass type IV membrane protein . This localization is consistent with its functional role in the endosomal-lysosomal trafficking pathway .

What are the common applications for STX7 antibodies in research?

STX7 antibodies are employed in various experimental techniques:

When selecting an antibody, researchers should verify that it has been validated for their specific application and experimental model .

What is the difference between polyclonal and monoclonal STX7 antibodies?

For critical experiments requiring reproducibility across long-term studies, monoclonal antibodies may offer advantages due to their consistency, while polyclonal antibodies can provide enhanced sensitivity by detecting multiple epitopes .

How should STX7 antibodies be stored and handled for optimal performance?

To maintain STX7 antibody integrity and performance:

• Storage temperature: Store at -20°C for long-term preservation

• Buffer composition: Most commercial STX7 antibodies are supplied in PBS with:

  • 50% glycerol as a cryoprotectant

  • 0.02-0.09% sodium azide as a preservative

  • Sometimes 0.5% BSA for stability

• Handling practices:

  • Avoid repeated freeze-thaw cycles

  • Aliquot into smaller volumes for single use

  • Store for up to 1 year from receipt date at -20°C

• Working dilution ranges:

  • Western Blot: 1:500-2000

  • IHC-P: 1:50-300

  • ICC/IF: Follow manufacturer's recommendations

Proper handling significantly impacts experimental outcomes, particularly for sensitive applications like immunohistochemistry.

What controls should be included when using STX7 antibodies for experimental validation?

Including these controls is essential for distinguishing genuine STX7 detection from technical artifacts, particularly in complex tissue samples or when investigating novel findings.

How can I validate the specificity of an STX7 antibody for my particular research application?

A comprehensive validation strategy for STX7 antibodies should include:

• Molecular weight verification: Confirm a 29.8 kDa band (for human STX7) in Western blot analysis, accounting for potential post-translational modifications

• Multi-technique confirmation:

  • If positive by Western blot, verify with immunocytochemistry to assess subcellular localization to endosomal structures

  • Compare staining patterns across independent antibodies targeting different STX7 epitopes

• Genetic validation approaches:

  • siRNA/shRNA knockdown: Demonstrate reduced antibody signal following STX7 depletion

  • CRISPR/Cas9 knockout: Show complete signal loss in knockout models

  • Overexpression: Observe increased signal in STX7-overexpressing cells

• Cross-reactivity assessment: Test the antibody against related syntaxin family members (particularly syntaxin-8, which shares functional overlap)

• Literature comparison: Compare your findings with published research using the same antibody. Several STX7 antibodies have associated citations that can provide reference data

What are the best protocols for optimizing STX7 antibody performance in different experimental techniques?

Western Blot Optimization:

• Sample preparation: Use RIPA buffer with protease inhibitors to effectively extract membrane-bound STX7

• Protein loading: 20-40 μg total protein per lane

• Blocking: 5% non-fat dry milk in TBST for 1 hour at room temperature

• Primary antibody: Incubate at recommended dilution (typically 1:500-2000) overnight at 4°C

• Detection: HRP-conjugated secondary antibody with enhanced chemiluminescence

Immunohistochemistry Optimization:

• Fixation: 10% neutral buffered formalin (optimal for preserving STX7 epitopes)

• Antigen retrieval: Citrate buffer (pH 6.0) heat-mediated retrieval

• Blocking: 10% normal serum from secondary antibody host species

• Primary antibody: Incubate at 1:50-300 dilution for 1-2 hours at room temperature or overnight at 4°C

• Detection: DAB chromogen provides optimal visualization of membranous staining

Immunofluorescence Optimization:

• Fixation: 4% paraformaldehyde for 15 minutes

• Permeabilization: 0.1% Triton X-100 for 10 minutes (critical for accessing STX7 epitopes)

• Primary antibody: Incubate at recommended dilution overnight at 4°C

• Co-staining: Consider dual labeling with endosomal markers (EEA1, Rab5, Rab7) to confirm localization

Always perform titration experiments to determine the optimal antibody concentration for your specific sample type and application.

How can I troubleshoot non-specific binding or high background when using STX7 antibodies?

For persistent issues, consider using an antibody targeting a different epitope region of STX7, as antibodies recognizing different parts of the protein (N-terminal vs. C-terminal) may have varying performance in specific applications .

What are the considerations for using STX7 antibodies across different species due to sequence homology?

STX7 is evolutionarily conserved across species, with orthologs reported in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken . When selecting an STX7 antibody for cross-species applications, consider:

When using STX7 antibodies across species:

• Select antibodies raised against conserved epitopes (compare sequence alignment)

• Verify reactivity claims in product documentation (many antibodies list validated species)

• Conduct preliminary validation in your species of interest before proceeding with extensive experiments

• Consider using higher antibody concentrations for non-validated species, but with appropriate negative controls

• For critical cross-species applications, sequence the immunogen region in your species of interest to assess potential epitope conservation

How can I quantitatively analyze STX7 expression using antibody-based techniques?

Western Blot Quantification:

• Use a loading control appropriate for your experimental context (β-actin, GAPDH, or α-tubulin)

• Employ digital imaging systems with linear detection range

• Analyze band intensity using software (ImageJ, Image Lab)

• Calculate relative expression as: STX7 signal intensity / loading control intensity

• Include a standard curve of recombinant STX7 for absolute quantification

Flow Cytometry:

• Use permeabilization buffer optimized for endosomal proteins

• Calculate mean fluorescence intensity (MFI) and compare to isotype control

• Use median fluorescence intensity for non-normally distributed populations

• For dual staining with endosomal markers, employ compensation controls

ELISA Approaches:

• Commercial STX7 ELISA kits are available for quantitative analysis

• Develop sandwich ELISA using capture and detection antibodies targeting different epitopes

• Generate standard curves using recombinant STX7 protein

• Ensure sample preparation methods effectively solubilize membrane-bound STX7

Immunohistochemistry Quantification:

• Use digital pathology software for unbiased analysis

• Quantify staining intensity on a standardized scale (0-3+)

• Assess percentage of positive cells and subcellular localization

• Calculate H-score = Σ(percentage of cells with intensity i) × i

What are the challenges in studying STX7 localization using immunofluorescence, and how can they be overcome?

Challenge 1: Distinguishing endosomal STX7 from other membrane compartments

• Solution: Perform co-localization studies with established markers:

  • EEA1 or Rab5 for early endosomes

  • Rab7 for late endosomes

  • LAMP1 for lysosomes

  • Quantify co-localization using Pearson's or Mander's coefficients

Challenge 2: STX7 epitope accessibility in membrane structures

• Solution: Optimize fixation and permeabilization:

  • Test different fixatives (PFA vs. methanol)

  • Use gentler permeabilization agents (saponin vs. Triton X-100)

  • Consider antigen retrieval methods for fixed tissue sections

Challenge 3: Low signal-to-noise ratio

• Solution: Employ signal amplification and background reduction:

  • Use tyramide signal amplification systems

  • Apply background-reducing reagents in antibody diluent

  • Utilize confocal microscopy with appropriate pinhole settings

Challenge 4: Dynamic localization of STX7 during vesicle trafficking

• Solution: Implement live cell imaging approaches:

  • Generate STX7-fluorescent protein fusions (careful to preserve functionality)

  • Use super-resolution microscopy techniques (STORM, PALM)

  • Conduct pulse-chase experiments with endocytic tracers

Challenge 5: Distinguishing specific from non-specific staining

• Solution: Include comprehensive controls:

  • STX7 knockdown/knockout cells as negative controls

  • Peptide competition controls to verify specificity

  • Secondary-only controls to assess background

What is known about STX7's role in cancer progression, particularly in invadopodia formation?

Recent research has identified STX7 as a key contributor to cancer cell invasion, particularly in breast cancer. The functional significance of STX7 in cancer includes:

• Invadopodia formation: STX7 localizes near invadopodia structures (specialized membrane protrusions) and contributes to their formation and function in MDA-MB-231 breast cancer cells

• Protease trafficking: STX7 co-traffics with MT1-MMP (MMP14), a critical matrix metalloproteinase, suggesting it regulates the delivery of proteases to invadopodia

• Degradative activity: Depletion of STX7 reduces both the number of invadopodia and their matrix-degrading capacity

• SNARE complex formation: STX7 forms distinct complexes with VAMP2, VAMP3, VAMP7, STX4, and SNAP23 during invadopodia formation

• Differential regulation of MT1-MMP pools: STX7 silencing specifically reduces invadopodia-associated MT1-MMP while increasing non-invadosomal pools

Methodological approaches to study STX7 in cancer include:

• Gene silencing (siRNA/shRNA) followed by invasion assays

• Total internal reflection fluorescence microscopy (TIRF-M) to visualize STX7 trafficking

• Co-immunoprecipitation to identify SNARE complex partners

• Gelatin degradation assays to assess invadopodia function

These findings suggest STX7 could be a potential therapeutic target for inhibiting cancer cell invasion and metastasis.

How does STX7 interact with other SNARE proteins, and what antibody-based approaches can be used to study these interactions?

STX7 forms various SNARE complexes that mediate specific fusion events in the endosomal pathway. Key interaction partners include:

Antibody-based approaches to study these interactions include:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate STX7 using purified antibodies (e.g., R&D Systems AF5478)

  • Analyze interacting partners by Western blot

  • Validate interactions with reciprocal Co-IP experiments

• Proximity Ligation Assay (PLA):

  • Use pairs of antibodies against STX7 and potential partners

  • Produces fluorescent signal only when proteins are within 40nm

  • Allows visualization and quantification of interactions in situ

• Fluorescence Resonance Energy Transfer (FRET):

  • Label STX7 and partner proteins with appropriate antibodies

  • Detect energy transfer between fluorophores when proteins interact

  • Provides spatial and temporal information about interactions

• Bimolecular Fluorescence Complementation (BiFC):

  • Express STX7 and partners as fusion proteins with complementary fragments

  • Visualize interaction through reconstituted fluorescence

  • Validate with antibody staining

• Pull-down assays:

  • Use GST-tagged STX7 to pull down interacting partners

  • Confirm identity using specific antibodies

  • Compare wild-type vs. mutant STX7 to map interaction domains

What contradictory findings exist in STX7 research, and how might antibody selection impact these inconsistencies?

Several areas of STX7 research show discrepancies that may be influenced by methodological differences, particularly antibody selection:

Subcellular localization discrepancies:

• Some studies report STX7 predominantly in early endosomes

• Others find it primarily in late endosomes and lysosomes

• Potential explanation: Antibodies targeting different epitopes may have varying accessibility in different subcellular compartments

Function in endosomal fusion:

• Contradictory reports on whether STX7 mediates early-to-early endosome fusion or late endosome-lysosome fusion

• Antibody-related factors: Blocking antibodies used in functional studies may have off-target effects on related syntaxins

Isoform-specific functions:

• Up to 2 isoforms of STX7 have been reported

• Inconsistent detection of isoforms may result from antibodies recognizing different epitopes

• Solution: Use isoform-specific antibodies when available and clearly report which isoforms are being studied

Species-specific findings:

• Some phenotypes observed in mouse models aren't replicated in human studies

• Antibody considerations: Ensure antibodies are validated for cross-species reactivity when comparing across model systems

Recommendations to address inconsistencies:

• Clearly document antibody catalog numbers, clones, and epitopes in publications

• Validate antibodies using genetic approaches (siRNA, CRISPR) for each experimental system

• Use multiple antibodies targeting different epitopes to corroborate findings

• Consider potential post-translational modifications that might affect epitope recognition

• Standardize experimental conditions across labs to minimize technical variability

How can STX7 antibodies be used to investigate the protein's role in endosomal-lysosomal trafficking disorders?

STX7 antibodies provide valuable tools for exploring endosomal-lysosomal trafficking disorders, which include various lysosomal storage diseases and neurodegenerative conditions:

Experimental approaches:

• Comparative expression analysis:

  • Quantify STX7 levels in patient vs. control samples using validated antibodies

  • Assess correlation between STX7 expression and disease severity

  • Methods: Western blot, immunohistochemistry, flow cytometry

• Subcellular localization studies:

  • Examine STX7 distribution in disease models using confocal microscopy

  • Co-stain with markers for endosomes (EEA1, Rab5, Rab7) and lysosomes (LAMP1)

  • Quantify co-localization coefficients to detect trafficking defects

• Functional assays:

  • Monitor endosomal maturation using pulse-chase experiments with fluorescent cargo

  • Assess effects of disease-associated mutations on STX7 function

  • Use antibodies to deplete or block STX7 and measure impact on endolysosomal pathways

• Protein-protein interaction analysis:

  • Compare STX7 SNARE complex formation in disease vs. normal conditions

  • Identify altered binding partners using co-immunoprecipitation

  • Employ proximity ligation assays to visualize interactions in situ

• Therapeutic monitoring:

  • Use STX7 antibodies to assess normalization of trafficking defects following experimental therapies

  • Develop assays to measure STX7-dependent processes as pharmacodynamic biomarkers

Disease relevance of STX7:

• Potential involvement in Hermansky-Pudlak syndrome (characterized by oculocutaneous albinism and bleeding disorders)

• Implications in neurodegenerative diseases like Alzheimer's where endolysosomal dysfunction occurs

• Possible role in disorders with impaired autophagy, as STX7 may participate in autophagosome-lysosome fusion

By strategically employing STX7 antibodies in these approaches, researchers can gain insights into the molecular mechanisms of endosomal-lysosomal trafficking disorders and potentially identify novel therapeutic targets.